Triple negative breast carcinoma is a prognostic factor in Taiwanese women by Lin, Che et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Triple negative breast carcinoma is a prognostic factor in 
Taiwanese women
Che Lin1, Su-Yu Chien2, Li-Sheng Chen1, Shou-Jen Kuo1, Tsai-Wang Chang*3 
and Dar-Ren Chen*1
Address: 1Comprehensive Breast Cancer Center, Changhua Christian Hospital, Changhua, Taiwan, 2Department of Pharmacology, Changhua 
Christian Hospital, Changhua, Taiwan and 3Department of General Surgery, National Cheng Kung University Hospital, Tainan, Taiwan
Email: Che Lin - chelin1chelin1@yahoo.com.tw; Su-Yu Chien - d4605@cch.org.tw; Li-Sheng Chen - 131032@cch.org.tw; Shou-
Jen Kuo - 40225@cch.org.tw; Tsai-Wang Chang* - twchang@mail.ncku.edu.tw; Dar-Ren Chen* - darren_chen@cch.org.tw
* Corresponding authors    
Abstract
Background: Currently, there is a debate as to whether triple negative breast carcinoma (TNBC)
has a worse prognosis than non-TNBC. Our aim was to determine whether TNBC is a prognostic
factor for survival.
Methods: We identified 1,048 Taiwanese breast carcinoma patients, of whom 167 (15.9%) had
TNBC. Data used for analysis were derived from our cancer registry database for women with
breast cancer who were diagnosed between 2002 January and 2006 December.
Results: In the Kaplan-Meier analysis, tumor subgroup (TNBC vs. non-TNBC) was a prognosis
factor related to 5-year overall survival. In the univariate analysis, tumor subgroup (TNBC vs. non-
TNBC) was a significant factor related to 5-year overall survival, in addition to age, tumor size,
lymph node, metastasis, grade, stage, estrogen receptor status, progesterone receptor status, and
HER2 overexpression status. In the multivariate analysis, tumor subgroup was not a significant
factor related to 5-year disease-free survival (DFS). In node-positive patients, tumor subgroup was
a significant factor related to 5-year overall survival, in addition to age, tumor size, metastasis, and
grade. In node-negative patients, tumor subgroup was not a significant factor related to 5-year
disease-free survival and 5-year overall survival.
Conclusion: Our results indicated that TNBC patients in Taiwan have worse 5-year overall
survival than non-TNBC patients. Notably, in node-positive patients, TNBC played a prognostic
role in 5-year overall survival.
Background
Many oncologists think breast cancer is a clinically heter-
ogeneous disease with different responses to treatment
and outcomes [1,2]. Sixty to 80% of tumors are positive
for the estrogen receptor (ER) and/or progesterone (PgR),
and 20% to 40% have her2/neu (HER2) gene over-expres-
sion [1]. Interestingly, some recent data suggested that tri-
ple negative breast carcinomas (TNBC), ER-negative, PgR-
negative and HER2-negative exhibited different clinical
outcomes [3,4]. However, there is uncertainty about the
appropriate survival role for TNBC. Information on the
TNBC subtype is still limited and confusing in adjuvant
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chemotherapies [4-15]. Liedtke revealed that patients
with TNBC have increased pathologic complete response
rates (pCR) compared with non-TNBC patients, and those
with pCR have excellent survival [3]. Liedtke also demon-
strated that patients with residual disease after neoadju-
vant chemotherapy have significantly worse survival if
they have TNBC compared with non-TNBC, particularly
in the first 3 years. Because these studies were done in the
other countries, their findings might not apply to Taiwan.
In this study, we sought to determine the risk associated
with TNBC in Taiwan.
Therefore, the aim of this study was to determine the prog-
nostic significance of TNBC with respect to disease-free
survival (DFS) and overall survival in a group of homoge-
neously-treated Taiwanese breast carcinoma patients.
Methods
Patients were identified from the databases of the cancer
registry at Changhua Christian Hospital, which is located
in central Taiwan. Data collection for cancer in this medi-
cal center began in 1986 and continued until 2009. The
well-trained case managers used the registry software and
collected uniform information about all patients with
breast cancer who had been examined at least once as out-
patients or inpatients in the daily clinical service. This
study was approved by the institutional review board of
Changhua Christian Hospital (IRB number: 080325). The
baseline data included demographic characteristics (e.g.,
age), tumor characteristics (e.g., tumor size, positivity of
lymph node, metastasis, grade, pathologic stage, ER/PgR/
HER2 information and histology). Patients with ductal
carcinoma in situ only were excluded. The data underwent
a variety of editing checks and procedures, so as to omit
duplicate records. The quality of the cancer registry data-
base was reviewed and approved by the committee, which
consisted of radiologists, oncologists, pathologists, sur-
geons and epidemiologists with special expertise in breast
cancer.
Tumor size was determined on the basis of pathological
reports from the Changhua Christian Hospital. The
Bloom-Richardson grading system was used for tumor
grading. This grading scheme is based on three morpho-
logic features: degree of tumor tubule formation, tumor
mitotic activity, and nuclear pleomorphism of tumor
cells. Seven possible scores are condensed into three
Bloom-Richardson grades: I, II, or III. Staging in this study
was presented by the American Joint Committee on Can-
cer stage group.
Immunohistochemistry (IHC) analysis was performed on
formalin-fixed, paraffin-embedded breast cancer tissue.
The ER and PgR analysis was based on a IHC assay, in
which a report of 10% or greater of cells that had nuclear
staining for ER was considered a positive result as well as
PgR. IHC was performed with anti-ER (NeoMarkers,
clone: SP1, dilution: 1:200, Fermont, California) and anti-
PgR antibody (NeoMarkers, clone:SP2, dilution: 1:250,
Fermont, California) by an autostaining system (Ventana
Medical Systems, Tucson, Arizona).
Breast cancer tumors were classified as HER2-positive if
they demonstrated HER2 gene amplification using the flu-
orescence in-situ hybridization method, or were scored as
3+ by an IHC method. HER2 IHC only used cell mem-
brane localization to interpret (Dako, Carpinteria, Cali-
fornia). The intensity of the membrane staining was
defined by a semiquantitative score (0 to 3+). Tumor
staining was compared to staining of normal breast epi-
thelium from the same patient as a negative control. For
clinical purposes, 3+ staining, defined as uniform and
intense membrane staining in more than 30% of invasive
breast cancer cells, was considered overexpression. No
staining or weak incomplete membrane staining was con-
sidered a negative result.
Data used for analysis were derived from the cancer regis-
try database of women with breast cancer who were diag-
nosed between 2002 January and 2006 December. Data
for analysis started from 2002, because there was a lack of
information on HER2 in patients before 2002. DFS was
defined as freedom from breast cancer recurrence or breast
death. Overall survival was defined as freedom from
breast cancer death or other causes of death.
Postoperative adjuvant therapy has been performed based
on the recommendation of NCCN or St. Gallen guidelines
with anthracycline-based regimens (in this study mostly
FEC therapy: 5-FU 500 mg/m2, epirubicin 75–90 mg/m2,
cyclophosphamide 500 mg/m2) as chemotherapy. Tax-
anes (paclitaxel, docetaxel) were added to follow FEC
therapy in few high risk patients.
The patient group included 1,048 females with an average
age of 51.8 years (standard deviation [SD] = 11.9 years).
Data are expressed as mean ± SD for continuous variables.
Independent t tests were used for the comparison of con-
tinuous variables. Categorical variables were normally
tested by the χ2 test when appropriate. All p values are
two-tailed; a p value of less than 0.05 was considered to
indicate statistical significance.
We used Cox proportional hazard analysis to assess the
risk of recurrence or mortality relative to the prognostic
factors in breast cancer cases. Cumulative survival rates of
breast cancer cases were analyzed by the Kaplan-Meier
method. The differences of cumulative survival were
assessed using the log-rank method. All statistical analyses
were performed with SAS 9.1 software.BMC Cancer 2009, 9:192 http://www.biomedcentral.com/1471-2407/9/192
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Results
Eighty-two (7.8%) patients died for cancer-related rea-
sons during their follow-up, up to 31, December 2007.
Five (0.48%) patients died for non-cancer-related rea-
sons. The average follow-up time was approximately 40
months. One hundred and sixty-seven patients (15.9%)
had TNBC and the remaining 881 patients (84.1%) were
defined as non-TNBC. There was no distributional differ-
ence of adverse prognostic factors between the two
groups, except lymph node, and grade (Table 1). Sev-
enty-one cases with recurrence of breast cancer were con-
sidered as the events.
Table 1: Descriptive statistics of women with breast cancer according to tumor subgroup
Features Total
(n)
Tumor subgroup p-value
TNBC
(n = 167)
non-TNBC
(n = 881)
Age, years (SD) 51.97 (13.04) 51.73 (11.79) 0.81
Tumor size, cm (%)
<2.0 446 46.1 46.3 0.9651
≥2.0 517 53.9 53.7
Other or Unknown 85
Lymph node (%)
Negative 553 70.1 54.8 0.0004*
Positive 413 29.9 45.2
Other or Unknown 82
Number of axillary lymph nodes involved (n)
1–3 210 45.7 51.8 0.6848
4–9 122 34.8 29.0
10+ 79 19.6 19.2
Average number of axillary lymph nodes involved per node-positive patient 6.17 (5.91) 6.19 (7.92) 0.99
Metastasis (%)
No 938 96.8 97.8 0.4781
Yes 23 3.2 2.2
Unknown 87
Metastasis site (n)
Bone 9 1 8
Lung 1 1 0
Liver 2 0 2
Other 2 0 2
Multiple 5 1 4
Unknown 4 2 2
Grade (%)
I ~II 693 43.4 73.8 <0.0001
III 311 56.6 26.2
Unknown 44
Stage
< II 315 35.1 32.7 0.5622
≥ II 638 64.9 67.3
Unknown 95
Estrogen receptor (ER)
Negative 369 100 23
Positive 675 0 77
Progesterone receptor (PR)
Negative 383 100 25
Positive 661 0 75
Her2/neu gene (HER2) overexpression
Negative 789 100 71
Positive 259 0 29
Histological types
Infiltrating duct carcinoma, NOS 939 91.6 89.2
Lobular Carcinoma, NOS 24 0 2.7
Mucinous adenocarcinoma 24 0 2.7
Infiltrating duct mixed with other types of carcinoma 18 1.8 1.7
Others 43 6.6 3.6BMC Cancer 2009, 9:192 http://www.biomedcentral.com/1471-2407/9/192
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The univariate analysis for prognostic factors associated
with 5-year DFS revealed that the tumor group, whether
TNBC or non-TNBC, as well as age and menopausal sta-
tus, was not statistically significant (Table 2). The univar-
iate analysis for prognostic factors associated with 5-year
overall survival revealed that the tumor group as TNBC or
non-TNBC was statistically significant, in addition to age,
tumor size, lymph node, metastasis, grade, stage, ER sta-
tus, and PgR status (Table 2).
The multivariate analysis for prognostic factors associated
with 5-year DFS revealed that the tumor group as TNBC or
non-TNBC was not statistically significant. The multivari-
ate analysis for prognostic factors associated with 5-year
overall survival revealed that the tumor group as TNBC or
non-TNBC was not statistically significant (Table 3).
Survival curves are shown in the figures. Figure 1 reveals
that TNBC tends to display a worse 5-year overall survival
(p = 0.0026) than non-TNBC, using by log-rank analysis.
ER-positive and/or PgR-positive and HER2-negative
patients had the best clinical outcome, with a 5-year DFS
of 80%; ER-negative, PgR-negative and HER2-positive
patients (HER2-positive subtype) showed the worst out-
come with a 5-year DFS of 45% (Figure 2A). TNBC has rel-
atively poor prognosis. Figure 3A shows ER-positive and/
or PgR-positive and HER2-negative patients had the best
clinical outcome, with a 5-year overall survival of 91%,
and the HER2-positive subtype showed the worst out-
come, with a 5-year overall survival of 59%.
To investigate the lymph node factor, we analyzed node-
positive and node-negative patients individually. For
node-positive patients, Figure 2B demonstrates that TNBC
breast carcinoma tends to show a worse 5-year DFS, by
log-rank analysis, and that ER-positive and/or PgR-posi-
tive and HER2-negative patients have the best 5-year DFS
(p = 0.0088). For node-negative patients, Figure 2C
reveals that the four subgroups do not show a 5-year DFS
difference, using log-rank analysis (p = 0.0720).
For node-positive patients, Figure 3B points out that
TNBC breast carcinoma patients tend to have the worst 5-
year overall survival, by log-rank analysis, and that ER-
positive and/or PgR-positive and HER2-negative patients
have the best 5-year overall survival (p  < 0.0001). For
node-negative patients, Figure 3C indicates that the four
subgroups do not show a 5-year overall survival differ-
ence, by log-rank analysis (p = 0.8620).
Discussion
We present the results of the largest Taiwanese study to
date that thoroughly investigates the clinical phenotype of
TNBC with regard to DFS and overall survival.
Traditionally, breast carcinomas have been classified as
hormone receptor-positive or negative. Recently, newer
approaches to breast carcinoma classification using gene-
expression profiles and IHC biomarkers have identified at
least four subtypes [10]. These subtypes are, luminal A
(ER-positive and/or PgR-positive and HER2-negative),
Table 2: Prognostic factors for 5-year disease-free survival (DFS) and overall survival in univariate Cox regression analysis
Features DFS Overall Survival
HR 95% CI p-Value HR 95% CI p-Value
Age 1.00 0.99–1.01 0.9859 1.03 1.01–1.04 0.0018
Menopausal status
(Postmenopausal vs. Premenopausal) 1.04 0.76–1.42 0.8132 1.51 0.98–2.33 0.0623
Tumor size, cm 1.22 1.16–1.29 <0.0001 1.20 1.11–1.31 <0.0001
Lymph node
(Positive vs. Negative) 3.08 2.14–4.42 <0.0001 2.83 1.71–4.68 <0.0001
Metastasis
(Yes vs. No) 4.25 2.22–8.11 <0.0001 9.40 4.78–18.49 <0.0001
Grade
(III vs. I ~II) 1.71 1.23–2.38 0.0014 2.03 1.31–3.16 0.0017
Stage
(≥ II vs. < II) 3.03 1.87–4.94 <0.0001 2.53 1.33–4.84 0.0048
ER status
(Negative vs. Positive) 2.26 1.64–3.12 <0.0001 3.08 1.98–4.79 <0.0001
PgR status
(Negative vs. Positive) 1.95 1.40–2.70 <0.0001 2.35 1.50–3.68 0.0002
HER2 overexpression status
(Negative vs. Positive) 1.97 1.41–2.75 <0.0001 1.56 0.99–2.46 0.058
Tumor subgroups
(TNBC vs. non-TNBC) 1.43 0.99–2.06 0.0570 1.99 1.26–3.13 0.0031BMC Cancer 2009, 9:192 http://www.biomedcentral.com/1471-2407/9/192
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luminal B (ER-positive and/or PgR-positive and HER2-
positive), basal-like (ER-negative, PgR-negative and
HER2-negative; mostly TNBC) and HER2-positive (ER-
negative, PgR-negative and HER2-positive). ER- and PgR-
negative tumors are generally thought to have a poor
prognosis because of a deficiency of hormone therapy
strategies. HER2-negative tumors lack the benefit of
HER2-targeted therapy and are thought to imply a worse
prognosis, as well [10]; however, few TNBC data have
been reported among non-Western populations. Our data
showed that TNBC in Taiwan may have a different mean-
ing than in Western countries.
Table 1 revealed TNBC subgroup had higher rates of node-
negative cases, in agreement with comparable studies
[4,12,16,17]. Some series had different results from ours
[3,6,7,10,13,14,18,19].
Our univariate Cox regression analysis demonstrated that
tumor size, lymph node status, metastasis, grade, stage, ER
status, PgR status, and HER2 status except tumor TNBC
subgroup were the prognostic factors for 5-year DFS, in
contrast to comparable series [4,6,17]. There were discrep-
ant findings between the outcomes of DFS and overall sur-
vival in our data. In CALGB 9344 trial, taxanes
demonstrated a statistically significant improvement in
DFS but not overall survival. It may interpret the discrep-
ancy. In this study the chemotherapy regimen of most
patients was FEC therapy. Due to Taiwan national health
insurance policy, using FEC followed by Taxanes was only
allowed in node-positive and ER negative breast cancer
women. In Taiwan node-positive TNBC patients were
allowed to receive Taxanes which improved DFS but not
overall survival. Furthermore, Yin et al showed 85.1% of
their patients were administered adjuvant chemotherapy
Table 3: Prognostic factors for 5-year DFS and overall survival in multivariate Cox regression analysis
Features DFS Overall Survival
HR 95%CI p-Value HR 95%CI p-Value
Age 1.00 0.98–1.01 0.9058 1.04 1.01–1.06 0.0013
Tumor size, cm 1.19 1.10–1.28 <0.0001 1.17 1.04–1.32 0.0110
Lymph node
(Positive vs. Negative) 2.65 1.79–3.92 <0.0001 2.36 1.35–4.12 0.0026
Metastasis
(Yes vs. No) 2.30 1.15–4.64 0.0193 6.63 3.13–14.09 <0.0001
Grade
(III vs. I ~II) 1.54 1.05–2.26 0.0269 2.11 1.23–3.62 0.0065
Tumor subgroups
(TNBC vs. non-TNBC) 1.28 0.82–1.99 0.2835 1.66 0.93–2.96 0.0881
Node-positive
Age 0.99 0.97–1.01 0.2960 1.04 1.01–1.07 0.0161
Tumor size, cm 1.23 1.10–1.37 0.0002 1.29 1.11–1.51 0.0011
Metastasis
(Yes vs. No) 2.37 1.15–4.88 0.0198 7.52 3.37–16.79 <0.0001
Grade
(III vs. I ~II) 1.49 0.93–2.36 0.0948 2.46 1.23–4.90 0.0109
Tumor subgroups
(TNBC vs. non-TNBC) 1.13 0.63–2.03 0.6847 2.20 1.08–4.49 0.0296
Node-negative
Age 1.02 0.99–1.04 0.1801 1.04 1.01–1.07 0.0186
Tumor size, cm 1.16 1.02–1.31 0.0236 1.00 0.74–1.36 0.9813
Metastasis*
(Yes vs. No) - - - - - -
Grade
(III vs. I ~ II) 1.49 0.75–2.94 0.2526 1.69 0.69–4.12 0.2525
Tumor subgroups
(TNBC vs. non-TNBC) 1.52 0.75–3.06 0.2461 1.28 0.47–3.19 0.6815
* Patients without metastasis were censor observations by the end of study periodBMC Cancer 2009, 9:192 http://www.biomedcentral.com/1471-2407/9/192
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of different regimens for 4–6 cycles [4]. Mersin said their
patients had adjuvant chemotherapy according to the cur-
rent guidelines at that time [6]. Fulford et al. reported DFS
and overall survival results that were different from ours.
Their study demonstrated that basal tumors, mostly
TNBC, exhibited a significantly better DFS and overall sur-
vival than non-basal tumors; however, the study was
based on 470 patients with grade III invasive ductal carci-
nomas diagnosed between 1975 and 1991. Twenty six
percent of the patients received adjuvant chemotherapy
[17].
Our multivariate Cox regression analysis demonstrated
that tumor subgroup (TNBC vs. non-TNBC) was not the
prognostic factor for 5-year overall survival These findings
were in contrast with those of previous studies [3,5,12-
14,20]. Liedtke reported that decreased 3-year overall sur-
vival was observed for patients with TNBC, compared
with non-TNBC (3-year overall survival rates: 74% vs.
89%; HR = 2.53; 95% CI, 1.77 to 3.57; p < 0.001) [3]. In
addition, our results are consistent with those from other
studies with respect to prognostic factors for overall sur-
vival [16]. Kim reported that basal-like carcinoma, mostly
TNBC, did not show survival difference between other
subgroups, except the HER2-positive subgroup.
To further study the lymph node factor, we stratified
patients into node-positive and node-negative groups. In
node-positive patients, TNBC breast carcinoma tended to
demonstrate the worst 5-year overall survival by log-rank
analysis (Figure 3B), and ER-positive and/or PgR-positive
and HER2-negative patients had the best 5-year overall
survival (p < 0.0001). Figure 3C shows four subgroups of
node-negative patients that did not reveal a 5-year overall
survival difference by log-rank analysis (p = 0.8620). Our
results are in contrast to those of a previous study by
Rakha, which reported that both univariate and multivar-
iate analyses showed basal phenotype, mostly TNBC, was
the only significant and independent prognostic marker
in the node-negative patients [10].
Contrary to our supposition, our data in multivariate
analysis showed that tumor subgroup (TNBC vs. non-
TNBC) was not a prognostic factor for DFS. This study also
revealed ER-positive and/or PgR-positive and HER2-nega-
tive patients had the best 5-year DFS, and the HER2-posi-
tive subtype showed the worst 5-year DFS. These findings
were consistent with those of a previous study [6]. Mean-
while, our results contrast with those from other studies in
terms of prognostic factors for DFS [3,4,12-14,20].
Liedtke reported that in multivariate analysis, a signifi-
cantly decreased progression-free survival was observed
for patients with TNBC compared with non-TNBC at the
seventh year [3]. Yin reported that in multivariate analy-
sis, TNBC had a significantly increased likelihood of
recurrence within 2 years after surgery rather than thereaf-
ter [4]. Recent studies demonstrated that TNBC tends
toward distant metastasis to the bone, soft tissue and vis-
cera [3,10]. Liedtke reported that TNBC has a higher pre-
dilection for visceral metastasis and early recurrence
within the first 3 years of follow-up [3]. Statistically, our
study did not substantiate a higher predilection of TNBC
factor for metastasis. In this study, there was no difference
in DFS and a significant difference in overall survival in
univariate analysis. This might indicate the difference in
overall survival after recurrence. In our study, treatment
Overall survival curves by tumor subgroup Figure 1
Overall survival curves by tumor subgroup. Triple negative breast cancer (TNBC) tended to display a worse 5-year 
overall survival (p = 0.0026) than non-TNBC, by log-rank analysis.
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Disease-free survival (DFS) curves according to patient group Figure 2
Disease-free survival (DFS) curves according to patient group. A, among 1,048 patients, ER-negative and PgR-negative 
and HER2-positive breast carcinoma tended to display the worst 5-year DFS, by log-rank analysis; ER-positive and/or PgR-pos-
itive and HER2-negative patients had the best 5-year overall survival; p < 0.0001. B, in the node-positive patients, TNBC 
tended to display a worse 5-year DFS by log-rank analysis; ER-positive and/or PgR-positive and HER2-negative patients had the 
best 5-year DFS; p = 0.0088. C, in the node-negative patients, four subgroups showed no 5-year DFS difference by log-rank 
analysis; p = 0.0720. We followed up the node-negative HER2-positive patients up to 48 months. ER, estrogen receptor; PgR, 
progesterone receptor; HER2, her2/neu gene over-expression.
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Overall survival curves according to patient group Figure 3
Overall survival curves according to patient group. A, among 1,048 patients, HER2-positive breast carcinoma tended to 
display the worst 5-year overall survival by log-rank analysis; our ER-positive and/or PgR-positive and HER2-negative patients 
had the best 5-year DFS; p < 0.0001. B, in the node-positive patients, TNBC tended to demonstrate the worst 5-year overall 
survival by log-rank analysis; ER-positive and/or PgR-positive and HER2-negative patients had the best 5-year overall survival; p 
< 0.0001. C, in the node-negative patients, four subgroups showed no 5-year overall survival difference, by log-rank analysis; p 
= 0.8620. We followed up the node-negative HER2-positive patients up to 48 months.
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after recurrence was based on NCCN or St. Gallen guide-
lines and multidisciplinary care discussions. Most patients
who have a recurrence after breast conservation therapy
were given completion mastectomy and adjuvant sys-
temic chemotherapy.
In node-positive patients, our data supported the ten-
dency of TNBC breast carcinoma to show a worse 5-year
DFS, by log-rank analysis (Figure 2B). These results con-
trast with those from a previous study [10]. In node-nega-
tive patients, our results revealed that the four subgroups
showed no difference in 5-year DFS or in 5-year overall
survival. However, these results contrast with those from
previous studies [10,21]. Rhee in Korea demonstrated that
triple-negativity was an independent predictor of shorter
relapse-free survival [21]. Table 1 in this study demon-
strates that TNBC had a higher ratio of lymph node-nega-
tive patients than non-TNBC. This may explain why
sometimes in our analysis the TNBC group was better
than the HER2-positive subgroup.
However, the heterogeneity of TNBC, follow-up time, case
number and other limitations may also explain the differ-
ences between our conclusions and those of previous
studies. Research into the heterogeneity of TNBC, new
neoadjuvant regimens and more molecular-based TNBC
classification studies could give us more information
about the optimal therapies for TNBC subgroups. Liedtke
et al. followed their patients to the 7th year, Yin to the
11th year, and Cheang to the 15th years [3-5]. A longer
follow-up period may yield different results.
In our study, the TNBC rate was 15.9%, which is similar
to reports from Korea and Carolina [16,18], but lower
than other reports [3-6,12,21]. The race factor could con-
tribute to the difference. Carey also reported that the
TNBC subtype has a higher incidence in pre-menopausal
African-American women (39%), compared to non-Afri-
can-American women of any age (16%) and post-meno-
pausal African-American women (14%) [18].
This study revealed TNBC and non-TNBC patients dis-
played a similar distribution of clinico-pathological char-
acteristics, such as age, tumor size, metastasis and stage, in
contrast to other Western studies [3,10,15,19]. These pre-
vious reports indicated that TNBC was associated with a
larger size, and therefore had a poorer outcome than non-
TNBC in terms of DFS and overall survival. In our study,
overall survival rates between these groups were statisti-
cally different in univariate analysis. This result may be
related to lymph node, as mentioned. On the other hand,
a higher grade was observed in our TNBC patients. In spite
of this finding, the DFS for the TNBC subgroup was not
statistically different from that of the non-TNBC sub-
group, in contrast to earlier studies [3,6,17].
In our study, all of the data inferred that HER2 status
added prognostic information for hormone receptor-pos-
itive breast cancer patients, confirming that luminal B
tumors constituted a poor outcome compared to luminal
A tumors, in accordance with other studies [5,6,22]. In
Taiwan, adjuvant trastuzumab targeted therapy was rarely
used before 2006 in the HER2-positive subtype, due to the
medical insurance policy, which may have contributed
substantially to the worst overall survival.
Some research about epidermal growth factor receptor
(EGFR) is interesting, and may provide another possible
answer for the question of TNBC prognostic value
[5,11,23]. Cheang reported that the expanded surrogate of
PgR, HER2, EGFR, and cytokeratin 5/6 indicate a more
specific definition of basal-like breast cancer, mostly
TNBC, which better predicts breast cancer survival [5].
Cheang also showed that the core basal group has 1.62
times greater risk for breast cancer-specific death, whereas
the non-core basal group does not have a clinically signif-
icant risk [5]. Siziopikou reported that because the major-
ity of TNBC patients express EGFR, the subgroup may
derive benefit from EGFR-targeted therapies [11].
Conclusion
In conclusion, our study indicates that TNBC tends to dis-
play a worse clinical course. Notably in node-positive
patients, TNBC does play a prognostic role in overall sur-
vival. In Taiwan, new strategies of chemotherapy and tar-
geted therapy should be investigated for patients with
TNBC.
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